Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma

doi:10.3760/cma.j.issn.1673-422X.2018.03.006

Abstract

Abstract: Objective To evaluate the expressions of CD68 and alpha/beta hydrolase domaincontaining protein 5 (ABHD5) in gastric carcinoma and their interrelation, and the relationship with the clinicopathological features of gastric carcinoma. Methods The immunohistochemistry staining was used to determine the expressions of CD68 and ABHD5 in 60 cases of gastric carcinoma and 30 cases of adjacent normal tissues. The relationships between CD68, ABHD5 and clinicopathological features of gastric carcinoma, and the correlation of them were analyzed. Results The expressions of CD68 and ABHD5 in gastric carcinoma were significantly higher than those in adjacent normal tissues, and the positive expression rates were 65.00% vs. 26.67% (χ2=11.779, P=0.001) and 60.00% vs. 30.00% (χ2=7.200, P=0.007) respectively, with significant differences. The expression of CD68 was related to TNM stage (χ2=7.959, P=0.005), lymph node metastasis (χ2=6.901, P=0.009) and serosal invasion (χ2=5.833, P=0.016), but it was not associated with pathological grade (χ2=0.028, P=0.866), gender (χ2=0.533, P=0.465) and age (χ2=0.060, P=0.807). The expression of ABHD5 was related to pathological grade (χ2=4.318, P=0.038), TNM stage (χ2=4.051, P=0.044) and serosal invasion (χ2=5.275, P=0.022), but it was not associated with lymph node metastasis (χ2=0.545, P=0.460), gender (χ2=0.191, P=0.662) and age (χ2=1.358, P=0.244). Contingency correlation analysis showed that there was positive correlation between CD68 and ABHD5 in gastric cancer (c=0.328, P=0.010). Conclusion The expressions of CD68 and ABHD5 in gastric carcinoma are higher than those in adjacent normal tissues, which are correlated with the different clinicopathological features of gastric carcinoma. The expression of CD68 is positively correlated with the expression of ABHD5. The combined detection of CD68 and ABHD5 expressions in gastric carcinoma is helpful to evaluate the invasion, metastasis and prognosis of gastric carcinoma.

Key words: Stomach neoplasms, Alpha/beta hydrolase domaincontaining protein 5, CD68

Yao Luyan, Wang Zian. Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma[J]. Journal of International Oncology, 2018, 45(3): 153-156.

References

［1］ Chanmee T, Ontong P, Konno K, et al. Tumorassociated macrophages as major players in the tumor microenvironment［J］. Cancers (Basel), 2014, 6(3): 1670-1690. DOI: 10.3390/cancers-6031670. ［2］ Noy R, Pollard JW. Tumorassociated macrophages: from mechanisms to therapy［J］. Immunity, 2014, 41(1): 4961. DOI: 10.1016/j.immuni.2014.06.010. ［3］ Biswas SK, Allavena P, Mantovani A. Tumorassociated macrophages: functional diversity, clinical significance, and open questions［J］. Semin Immunopathol, 2013, 35(5): 585-600. DOI: 10.1007/s0028101303677. ［4］ Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins［J］. Blood, 1993, 81(6): 1607-1613. ［5］ Liang M, Mulholland DJ. Lipogenic metabolism: a viable target for prostate cancer treatment?［J］. Asian J Androl, 2014, 16(5): 661-663. DOI: 10.4103/1008-682x.132947. ［6］ Sanders MA, Zhang H, Mladenovic L, et al. Molecular basis of ABHD5 lipolysis activation［J］. Sci Rep, 2017, 7: 42589. DOI: 10.1038/srep42589. ［7］ Miao H, Ou J, Peng Y, et al. Macrophage ABHD5 promotes colorectal cancer growth by suppressing spermidine production by SRM［J］. Nat Commun, 2016, 7: 11716. DOI: 10.1038/ncomms11716. ［8］ Brown JM, Chung S, Das A, et al. CGI58 facilitates the mobilization of cytoplasmic triglyceride for lipoprotein secretion in hepatoma cells［J］. J Lipid Res, 2007, 48(10): 22952305. DOI: 10.1194/jlr.M700279-JLR200. ［9］ Miao H, Ou J, Ma Y, et al. Macrophage CGI58 deficiency activates ROSinflammasome pathway to promote insulin resistance in mice［J］. Cell Rep, 2014, 7(1): 223235. DOI: 10.1016/j.celrep.2014.02.047. ［10］ Huang CY, Fong YC, Lee CY, et al. CCL5 increases lung cancer migration via PI3K, Akt and NFkappaB pathways［J］. Biochem Pharmacol, 2009, 77(5): 794-803. DOI: 10.1016/j.bcp.2008.11.014. ［11］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646674. DOI: 10.1016/j.cell.2011.02.013. ［12］ Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumorassociated macrophages in solid tumor: a metaanalysis of the literature［J］. PLoS One, 2012, 7(12): e50946. DOI: 10.1371/journal.pone.0050946. ［13］ Hashmi S, Wang Y, Suman DS, et al. Human cancer: is it linked to dysfunctional lipid metabolism?［J］. Biochim Biophys Acta, 2015, 1850(2): 352-364. DOI: 10.1016/j.bbagen.2014.11.004. ［14］ Santos CR, Schulze A. Lipid metabolism in cancer［J］. FEBS J, 2012, 279(15): 2610-2623. DOI: 10.1111/j.17424658.2012.08644.x.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.